The optimal levothyroxine (LT4) dose to treat congenital hypothyroidism (CH) remains unclear, with debate over whether higher starting doses (.10 mg/kg) are necessary and safe for a normal intelligence quotient (IQ).
neonatal period, that intellectual outcomes improved to an average normal intelligence quotient (IQ) (2, 3) . However, whether complete normalization of cognitive outcome is possible remains controversial, as some studies have found significant gaps compared with control populations, including healthy siblings (4, 5) . Furthermore, there is evidence that quality of life (QoL) scores are lower than those in the general population (6) .
To explain these suboptimal outcomes, it has been argued that either the fetal period of overt hypothyroidism interferes irretrievably with neuronal development or that postnatal treatment protocols are not sufficient (7) . Further outcome studies supported the latter argument, with late onset of postnatal treatment and a lower thyroxine (T4) dosage indeed significantly correlated with a lower IQ in patients with CH (8, 9) . On the basis of these retrospective data, higher starting doses of .10 mg/kg and commencement of treatment within the first 2 weeks of life were recommended (10) . The most recent outcome study from New Zealand, reporting that patients were treated according to a regimen consistent with these recommendations, documented that IQ at a mean age of 9.6 years was not different from that of sibling controls (11) .
Nevertheless, treatment with higher starting doses in studies in rodents (12) and patients with neonatal hyperthyroidism has raised concerns regarding the adverse effects of supraphysiological T4 levels, suggesting abnormal central nervous system development (13) . In addition, it has been repeatedly shown that the recommended high levothyroxine (LT4) dose of .10 mg/kg resulted in free T4 (fT4) levels in newborns and infants with CH that exceeded the reference ranges for this age group (14, 15) . This led some authors to caution against "overtreatment," although no unequivocal clinical symptoms of hyperthyroidism have been reported (16) . Moreover, data have been published recently that argue for decreased cognitive function in older children who were started on high-dose treatment and who reached favorable cognitive outcome measurements at a younger age (17, 18) . Although the number of patients in this study was very small and the lower IQ outcome was not associated with suppressed thyrotropin (TSH) levels, the authors advocated against the use of high-dose LT4 treatment in CH (18) .
To date, no long-term outcome data are available in adult patients with CH treated with a high LT4 starting dose compared with unaffected sibling controls. We hypothesized that a high initial LT4 dose (.10 mg/kg) is necessary for a normal IQ outcome and that the concurrent high T4 values in the first 2 years of life do not adversely affect cognitive outcomes during adolescence. We report here the outcomes of a long-term, single-center cohort study in 76 patients with CH at a mean age of 18 years who were treated with a mean LT4 dose of 13.5 mg/ kg starting at median age 8 days. Our study allowed the comparison of formal IQs tested by an experienced psychologist, further cognitive tests, and QoL with those of healthy sibling controls.
Methods

Subjects
All included patients were diagnosed in the Berlin screening program, which was established in 1978. Patients were recruited from the Department of Pediatric Endocrinology of the Charité Universitätsmedizin Berlin, where they had been treated on an outpatient care basis. Those who already transferred to adult endocrinologists were contacted by invitation letter.
Inclusion criteria were age of at least 10 years by the end of the study recruitment period (December 2013), treatment in our clinic until at least the second year of life, and availability of follow-up data from this period. Exclusion criteria were transient CH (normal thyroid function after therapy withdrawal, performed at the age of ;2 years), syndromic diseases, and genetic conditions likely to cause mental retardation (e.g., Down syndrome or NKX2.1 defect) (Fig. 1) . Controls, who were recruited among healthy siblings of the included patients, were .10 years of age and had normal thyroid function.
For more details on the cohort and treatment modalities; definitions of disease severity, TSH, T4, and T3 overtreatment; and duration of exposure to TSH, T4, and T3 overtreatment, see the Supplemental Appendix.
Study design
The study comprised a preexamination [blood sampling for thyroid function and metabolic parameters and ultrasonographic examination of the thyroid and intima media thickness (IMT)] and a main examination consisting of neurocognitive testing. Patients were included in the evaluation as long as their fT4 level was not below the reference values (8.7 to 16.4 ng/L).
Cognitive, anthropometric, metabolic, and QoL outcomes were compared with those of healthy sibling controls using a cross-sectional design.
Main study outcome parameters IQ in adolescents aged #16.9 years was assessed with the German version of the Wechsler Intelligence Test for Children-IV (19) . Participants older than 16.9 years were tested with "Wechsler Intelligenztest für Erwachsene," a German adaptation of the Wechsler Adult Intelligence Scale III (20) . Both of these tests are standardized tools for estimation of IQ with a mean 6 standard deviation (SD) of 100 6 15. A single experienced pediatric psychologist who was blinded to the study group carried out all measurements.
QoL was evaluated with the self-assessment 4-week recall form of the German version of the short form-36 Health Survey, standardized for subjects aged $15 years (21) . Scores were presented as two main domains: Physical Component Summary and Mental Component Summary, with a mean 6 SD score of 50 6 10. Figure 1 . Flowchart of the recruitment process. Of the 122 potentially recruitable patients with CH, 18 were excluded from the study because of the following reasons: Down syndrome (n = 1), Goldenhar syndrome (n = 1), NKX2.1 mutation (n = 3), major central nervous system malformation (n = 1), other not nearly specified syndromic disease (n = 1), sensorineural deafness in the first years of life (n = 6), missing treatment data for the first 24 months of life (n = 3), and having been tested with the same IQ test as used in our study within the last 2 years (n = 2). Of the 88 patients who agreed to participate in our study and underwent preexamination, six patients withdrew study consent, and the other six did not reach normal fT4 levels in repetitive measurements during the study period. 
Socioeconomic status
Parental socioeconomic status (SES) was determined by educational background and occupation (22) .
Statistical analysis
If not mentioned otherwise, statistical calculations were performed using IBM SPSS (version 22). Descriptive statistics are reported as mean 6 SD for parametric data and as median (range) for skewed data. Associations between continuous variables were examined using the Pearson correlation for normally distributed variables and the Spearman rank order correlation for skewed distributed variables. For pair-matched analysis between patients with siblings in the control group and the sibling nearest to them in age, the paired Student t test or Wilcoxon signed rank test was used.
Differences between the patient cohort and the control cohort were analyzed by using two-level linear mixed models (random intercept models), with the individual measures at the first level and the families as level two units to account for the clustering of the data through measuring siblings in families. Model-based estimates for patients and controls and corresponding P values were reported. For this analysis, SAS PROC MIXED (SAS 9.4) was used. A two-sided significance level of 0.05 was used, with no adjustment for multiple testing.
For detailed information about the statistical methods used, see the Supplemental Appendix.
Meta-analysis of initial T4 dose vs IQ
For a detailed description of the systematic review and metaanalysis, see the Supplemental Appendix.
Ethics approval
This clinical study was approved by the ethics committee of Charité-Universitätsmedizin Berlin (EA2/149/11). Written informed consent was obtained from all patients and controls as well as from parents or guardians in cases involving minor participants.
Results
Characteristics of the study groups CH group: Between 1979 and 2003, a total of 178 cases of permanent CH were diagnosed at the Berlin Neonatal Screening Center. The overall incidence was 1 per 3600 screened neonates. Medical records of 153 patients were available; 31 of these patients were lost to follow-up. Among 122 potentially recruitable patients, 104 met the inclusion criteria, of whom 88 participated (response rate, 85%). Eventually, 76 patients (68% females) aged 10.1 to 31.6 years (mean, 18.1 years) completed the study (Fig. 1) . Predominantly on the basis of ultrasonographic evaluation, the majority (83%) were affected by thyroid dysgenesis (58% of these with athyreosis), and 15 presented with severe CH (initial T4, #2 mg/dL). The 76 included patients did not differ from the general CH cohort in terms of sex and thyroid morphology.
Treatment was initiated at a median age of 8 days (range, 1 to 77 days), with a mean LT4 dose of 13.5 mg/kg per day (range, 4.4 to 20.8 mg/kg). TSH values normalized within a median of 15 days after start of treatment (range, 5 to 133 days), corresponding to an age of 24 days, whereas T4 values normalized within 8 days (range, 0 to 78 days), corresponding to a median age of 18 days (data not shown).
Control group: A total of 40 healthy siblings (24 females) aged 10.4 to 37.3 years (mean, 19.8 years) were enrolled in the control group. There were no significant differences in age or sex distribution between the two study groups (Table 1) . However, 22% of the patients had a low SES vs 41% of controls (P = 0.037). Therefore, IQ differences between the two study groups were estimated with a mixed-effects model adjusted for age, sex, and SES, using a family identification number to recognize sibling clusters.
Thyroid function at time of investigation
Most patients (62%) were still treated in the pediatric department, whereas the remainder had transitioned to adult medicine. Of the initial 88 study participants, 32 patients (36%) needed therapy adjustment. Of these, fT4 remained low in six (Fig. 1 ), so they were excluded from cognitive testing. For the 76 included patients, the median TSH value was 1.68 mU/L, with 26% of values being suppressed (minimum, 0.02 mU/L) and 13% being elevated (up to 24.6 mU/L). Patients' mean fT4 levels amounted to 16.7 ng/L (range, 10.7 to 25.7 ng/L) and were elevated in 53% (Fig. 2A) . The siblings' median serum TSH level was 2.19 mU/L, with no suppressed or elevated levels (Fig. 2B ).
Long-term cognitive outcome and QoL
Patients and siblings showed no significant difference in overall IQ (Table 2 ). There was a significant correlation between overall IQ values and individual SES (P , 0.001). With application of a mixed-effects model adjusted for SES, age, and sex, IQ values were 102.5 and 102.3 for patients and controls, respectively. Because there was a significant difference in SES between patients having siblings in the control group and those without siblings (data not shown), we also performed a pairmatched analysis in these sibling pairs (n = 36); here we also found no significant difference in overall IQ (P = 0.487). A range of further tests specific for cognitive abilities, attention, memory, and fine-motor skills were not significantly different between patients and controls ( Table 2 ). We performed a statistical analysis to examine possible effects of the patients' TSH and fT4 levels at the time of cognitive testing on the IQ results and found no significant correlation between TSH or fT4 and IQ (P = 0.318 and P = 0.281 for TSH and fT4 level, respectively). There was no difference in either component of the QoL score (i.e., Physical Component Summary or Mental Component Summary) between patients with CH and siblings (data not shown).
Somatic and metabolic parameters
In adjusted models, patients and siblings did not significantly differ in any of the tested parameters of somatic, metabolic, and cardiovascular outcomes, including height, body mass index, homeostatic model assessment, fasting blood glucose, insulin, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, IMT, blood pressure, or heart rate ( Table 1) . In patients, somatic parameters did not significantly correlate with fT4 level at the time of testing (data not shown).
Influence of baseline treatment variables and thyroid hormone levels in the first 24 months of life on IQ We did not find any significant correlation between IQ score and baseline treatment variables, including age at the start of therapy, initial LT4 dose per kilogram, or age at TSH and T4 normalization (data not shown).
The mean TSH level in the first 24 months of life was normal (3.49 mU/L; range, 0.28 to 32.7 mU/L), as was mean total-T3 level (1.79 ng/mL; range, 1.38 to 2.3ng/mL), whereas mean total-T4 level was elevated (14.9 mg/dL; range, 10.3 to 19 mg/dL). TSH was suppressed below the age-related reference range in all but six patients at least once, with a mean of 45% episodes. Elevated T4 levels occurred in all but one patient, with a mean of 58% episodes; elevated T3 levels occurred in 37 patients, with a mean of 11%. There was no significant correlation between IQ and individual mean TSH, T4, and T3 values; percentage of episodes of suppressed TSH, elevated T4, or elevated T3 (Fig. 3) ; and duration of exposure to TSH, T4, or T3 overtreatment (data not shown) in the first 2 years of life. In 33 of the 76 children, the LT4 dose was reduced at least once; however, only one of these children demonstrated irritability as a potential sign of hyperthyroidism, and no further unequivocal symptoms of hyperthyroidism were documented (data not shown).
Systematic review of initial thyroxine dosage and cognitive outcome
We identified 10 published studies that reported an association between cognitive outcome, severity of CH, and dosage at start of treatment. These 10 studies and the current study reported outcomes on 438 patients with CH: 156 with severe CH (initial serum T4 #2 mg/dL or fT4 #3 pmol/L) and 282 with moderate or mild CH (initial serum T4 .2 mg/dL or fT4 .3 pmol/L) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . The initial LT4 dose was classified as high (.10 mg/kg), median (8 to 10 mg/kg), and low (,8 mg/kg). In 157 of the total population (36%; 47 with severe CH and 110 with mild/moderate CH), treatment was started with a high initial LT4 dose. Patients with severe CH treated with a low initial LT4 dose had significantly lower IQ scores Only in the subgroup treated with a high initial LT4 dose .10 mg/kg per day was there no significant IQ difference between patients affected by severe CH vs mild/moderate CH (Fig. 4) .
Differences in fT4 and T3 at time of cognitive testing
Because we found an elevated mean T4 level during the first 24 months of life whereas mean TSH and mean T3 levels were normal in the same period (Fig. 3) , we hypothesized that patients with CH had a higher need for T4 in order to normalize TSH. To further explore this potential "T4 resistance" in patients with CH, we analyzed serum fT4 and total-T3 values in the same patients as young adults at the time of cognitive testing. When comparing thyroid hormone levels only in those sibling pairs with normal TSH values, we again found a significantly higher and even elevated fT4 level in patients with CH (Fig. 2C) . At the same time, the T3 level was in the normal range but was significantly lower in patients with CH than in their sibling controls (Fig. 2D) . These findings in sibling pairs with normal TSH values argue against LT4 overtreatment, in that the elevated T4 level does not result in an elevated T3 level and does not suppress TSH.
Discussion
Forty years after the introduction of CH screening programs, a controversy remains regarding the optimal initial LT4 dose. Despite the remarkable improvement in cognitive development due to early screening-based diagnosis and initiation of LT4 treatment within the first days of life, conflicting results from long-term outcome studies examining the effect of LT4 dosage have hampered unequivocal recommendations to maximize optimal outcomes. In particular, a recent study from New Zealand found no IQ difference in patients with CH treated with high-dose LT4 (10 to 15 mg/kg per day) compared with their sibling controls at a mean age of 9.6 years (11). Although this New Zealand study gave evidence for the recommended high starting dose, another study from the Netherlands suggested that initial highdose treatment leading to overtreatment impaired longterm IQ outcomes in older adolescents (18) .
In this longitudinal study from Berlin, we report final outcome data in young adult patients with CH treated with a high LT4 dose compared with sibling controls. We provide evidence that initial treatment with a mean LT4 dose of 13.5 mg/kg per day led to an indistinguishable normal IQ compared with those of a sibling control group. In addition, we showed that these patients were not different from their siblings in terms of body mass index, height, cardiovascular function, and QoL.
Inclusion of these favorable outcome results into sets of published IQ outcome data from a meta-analysis (24) (25) (26) (27) (28) (29) (30) (31) (32) revealed that severely affected patients achieved results similar to those of patients with milder CH forms only when treated with the higher starting dose of .10 mg/kg, not in those groups treated with lower LT4 doses. Together, our sibling-controlled young adult outcome data as well as the meta-analysis of available cohorts strongly argue that a higher LT4 dose .10 mg/kg not only enabled optimal cognitive development that was indistinguishable from that of the control group but also helped close the developmental gap between patients with severe and mild CH forms. Although it led to constantly elevated serum T4 levels, this high starting dose did not result in overt clinical hyperthyroidism-neither during infancy nor in young adulthood. Therefore, high-dose treatment of CH seems to be necessary to reach optimal cognitive development, while at the same time, it is safe in not causing clinical symptoms of hyperthyroidism.
To specifically address the recent study (18) , which showed a difference of 216 IQ points at the age of 11 years in patients exposed to long vs short fT4 overtreatment in the first 2 years of life, we explored our cohort for potential negative effects of high-dose therapy during the first 2 years of treatment. We found no correlation between the final IQ score and the mean elevated T4 level, high percentage of episodes of elevated T4 (58%), or duration of exposure to elevated T4. At the same time, we did not find a negative influence of suppressed TSH or increased T3 value. These contradictory findings might be due to the fact that in contrast to the described study (18) , our data were based on a large single-center cohort and on serum values that were collected in a single laboratory. Furthermore, small sample sizes in the subgroup comparisons might have biased the results (18) . Therefore, our data do not support the recently published assumption (18) that elevated T4 levels during infancy will eventually impair cognitive outcomes in young adulthood. In contrast, treatment in our cohort with a high LT4 dose resulted in optimal IQ scores in young adult patients with CH that were not different from IQ scores of sibling control. This is remarkable, as another study in young adult patients with CH with sibling controls who were treated with ,10 mg/kg per day demonstrated a gap of 8 IQ points (4). . Forest plot of mean IQ difference between patients with severe vs moderate/mild CH. We compared the IQ of patients with severe vs moderate/mild CH in subgroups treated with low (,8 mg/kg per day), median (8 to 10 mg/kg per day), and high (.10 mg/kg per day) initial LT4 dose. Severe CH was defined as an initial T4 level #2 mg/dL or a fT4 level #3 pmol/L. A total of 10 studies identified in the literature search that provided the necessary treatment parameters (n = 378 patients) were included in the meta-analysis, as well as n = 60 patients from our current cohort (reasons for exclusion were missing data on CH severity in 5patients and initial LT4 dose ,10 mg/kg/d in 11 patients, 1 with severe CH and 10 with moderate/mild CH). For interpretation, please see the text. CI, confidence interval.
Higher-than-normal T4 levels were reported previously in a variety of CH cohorts who were treated with the aim of rapidly normalizing TSH values (14, (33) (34) (35) . In patients with complete thyroidectomy, LT4 substitution aimed at normalizing TSH led to higher serum T4 levels than in normal control individuals (36, 37) . Moreover, a treatment efficacy study comparing patients with CH with those affected by acquired hypothyroidism revealed that a significantly higher daily LT4 dose was necessary to reach a normal TSH level, especially in patients with CH (2.16 mg/kg) compared with patients with acquired hypothyroidism (1.73 mg/kg) (38) . At the same time, the authors found a significantly higher serum fT4 value in patients with CH, whereas there was no difference in fT3 values (38) . We found similar results in our cohort: During the first 2 years of treatment with markedly elevated T4 levels, the mean serum T3 and TSH levels were normal. In addition, in those young adult patients with CH and normal TSH levels, we found significantly higher serum T4 levels than in their sibling controls, whereas T3 levels, although in the normal range, were significantly lower. Together, these published data combined with our findings consistently show that in patients with CH, high T4 levels are associated with normal TSH and normal T3 levels. Therefore, the higher T4 levels in patients with CH may not represent a state of "overtreatment" but may rather reflect a higher need for T4 to reach normal T3 levels, at least in the brain structures that regulate TSH.
So far, the molecular nature of this particular "T4 need" in patients with CH remains unclear. A comparable state of higher serum T4 level while T3 and TSH levels are normal was described for the rare inherited enzyme defect SBP2, which results in less-efficient deiodination (39) . Therefore, comparably lower efficiency of deiodinases might-for whatever reason-exist in patients with CH and needs now to be elucidated. In addition, the lack of appropriate thyroidbased direct T3 production could be part of this condition.
Despite the fact that our study group was small and we had only a limited sibling-control group (36 of 76) overall, after decades of neonatal screening and recent confusion about an "unfavorable" outcome with highdose LT4 treatment, we now provide evidence that the present recommendations of a high initial dose .10 mg/ kg is necessary, efficient, and safe to achieve optimal cognitive development in all patients with CH, including those who are severely affected.
Treatment of patients with CH with LT4 is straightforward and enables achievement of a normal IQ. However, at the same time, treatment is challenging as depicted by the high proportion of patients with elevated T4 and/or fT4 levels in infancy as well as in young adulthood, which seems necessary to normalize TSH levels, and the high rate of young adult patients with CH who did not have normal TSH levels in our and other (40) cohorts. An individualized treatment approach and close continuous monitoring of patients with CH-especially those with mild forms who may need lower LT4 doses and during and after transition into adult medical care-is therefore mandatory.
